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Polynucleotides are anionic macromolecules which are expected to transfer into the 
targeted cells through specific uptake mechanisms.  So, we developed polynucleotides 
coating complexes of plasmid DNA (pDNA) and polyethylenimine (PEI) for a secure 
and efficient gene delivery system and evaluated their usefulness.  Polyadenylic acid 
(polyA), polyuridylic acid (polyU), polycytidylic acid (polyC), and polyguanylic acid 
(polyG) were examined as the coating materials.  pDNA/PEI/polyA, pDNA/PEI/polyU, 
and pDNA/PEI/polyC complexes formed nanoparticles with a negative surface charge 
although pDNA/PEI/polyG was aggregated.  The pDNA/PEI/polyC complex showed 
high transgene efficiency in B16-F10 cells although there was little efficiency in 
pDNA/PEI/polyA and pDNA/PEI/polyU complexes.  An inhibition study strongly 
indicated the specific uptake mechanism of pDNA/PEI/polyC complex.  
Polynucleotide coating complexes had lower cytotoxicity than pDNA/PEI complex.  
The pDNA/PEI/polyC complex showed high gene expression selectively in the spleen 
after intravenous injection into mice.  The pDNA/PEI/polyC complex showed no 
agglutination with erythrocytes and no acute toxicity although these were observed in 
pDNA/PEI complex.  Thus, we developed polynucleotide coating complexes as novel 
vectors for clinical gene therapy, and the pDNA/PEI/polyC complex as a useful 
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candidate for a gene delivery system. 
 




1.  Introduction 
  Gene therapy is expected to be an effective method to treat cancer, infectious diseases, 
innate immunodeficiency, and cardiovascular diseases (Cavazzana-Calvo et al., 2012; 
Zarogouldis et al., 2012; Su et al., 2012).  Nucleic acids such as plasmid DNA (pDNA), 
antisense oligonucleotide, and small interfering RNA (siRNA) are used as therapeutic 
agents.  The success of gene therapy highly depends on the development of an 
effective and secure gene delivery system, but there are many obstacles to the delivery 
of naked nucleic acids, such as rapid enzymatic degradation, rapid elimination via the 
kidney, and poor cellular uptake because of their large molecules and anionic charge, 
which govern biodistribution in the body (Nishikawa et al., 2005; Sato et al., 2007).  In 
order to overcome these obstacles, a number of viral and non-viral vectors for nucleic 
acids have been developed for targeting cells and tissues through specific mechanisms 
(Nishikawa et al., 2005; Kurosaki et al., 2011; Corey, 2007; Tagalakis et al., 2011; 
Kawakami et al., 2000).  Non-viral vectors for gene delivery have emerged as a 
promising alternative to viral vectors, because non-viral vectors have advantages such 
as much lower immunotoxicity, a clear structure, and easy modeling (Liu et al., 2004).  
Cationic compounds, such as cationic polymers and cationic liposomes, are mainly used 
as the non-viral vectors.  On the other hand, Anionic polymers are little used as the 
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gene delivery vectors because they repulse the cellular membrane electrostatically and 
are not taken up by cells. 
However, several anionic polymers have been reported to be selectively taken up by 
endothelial cells, smooth muscles, and macrophages (McCourt et al., 2004; McCourt et 
al., 1999; Qian et al., 2009; Martens et al., 2006; Li et al., 2009).  Among them, 
polyguanylic acid was found to bind the scavenger receptor (SR) family (Class A, Class 
C, Class E, and Class F) (Gough et al., 2000).  The SR was originally coined to 
describe a macrophage receptor that mediates endocytosis of a broad range of 
polyanionic molecules.  Takakura et al. also demonstrated specific cellular uptake of 
pDNA in murine dendritic cells DC2.4 because the cellular association of pDNA was 
inhibited by pDNA itself, polyinosinic acid, and dextran sulfate (Yoshinaga et al.; 2002).  
Following intravenous injection, pDNA was rapidly eliminated from the circulation and 
taken up by liver sinusoidal endothelial cells (Hisazumi et al., 2004).  These results 
suggest a potential of polynucleotides for an effective gene delivery system using a 
specific uptake mechanism.  However, there are no reports on the development of 
nanoparticles using polynucleotides. 
  In the present study, we prepared ternary complexes using pDNA, polyethylenimine 
(PEI), and polynucleotide for a gene delivery system and evaluated their usefulness.  
5 
 
PEI is widely used as a polymeric vector.  Polynucleotides with large molecular and 
relatively stable properties were used as coating materials, including polyadenylic acid 
(polyA), polyuridylic acid (polyU), polycytidylic acid (polyC), and polyguanylic acid 
(polyG).  We newly found that ternary complexes coated by polyC were a useful 






2.  Materials and methods 
2.1.  Chemicals 
PEI (branched form, average molecular weight of 25,000) and rhodamine B 
isothiocyanate were purchased from Aldrich Chemical Co. (Milwaukee, WI, USA).  
Polyadenylic acid potassium salt (polyA), polyuridylic acid potassium salt (polyU), 
polycytidylic acid potassium salt (polyC), and polyguanylic acid potassium salt (polyG) 
were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA).  Fetal bovine serum 
(FBS) was purchased from Biological Industries Ltd. (Kibbutz Beit Haemek, Israel).  
RPMI 1640, Opti-MEM I, antibiotics (penicillin 100 U/mL and streptomycin 100 
µg/mL), and other culture reagents were obtained from GIBCO BRL (Grand Island, NY, 
USA).  2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt (WST-1) and 1-methoxy-5-methylphenazinium methylsulfate 
(1-methoxy PMS) were purchased from Dojindo Laboratories (Kumamoto, Japan).  
Rhodamine-PEI (Rh-PEI) was prepared in our laboratory.  Briefly, PEI and rhodamine 
B isothiocyanate were dissolved in dimethyl sulfoxide (DMSO) and stirred overnight at 
room temperature in the dark.  Rh-PEI was purified by gel filtration.  Almost 1.5% of 
PEI nitrogen was labeled with rhodamine B.  All other chemicals were of the highest 




2.2.  Preparation of pDNA and ternary complexes 
pCMV-Luc was constructed by subcloning the Hind III/Xba I firefly luciferase cDNA 
fragment from the pGL3-control vector (Promega, Madison, WI, USA) into the 
polylinker of the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA).  Enhanced green 
fluorescence protein (GFP) encoding the pDNA (pEGFP-C1) was purchased from 
Clontech (Palo Alto, CA, USA).  The pDNA was amplified using an EndoFree 
Plasmid Giga Kit (QIAGEN GmbH, Hilden, Germany).  The pDNA was dissolved in 
5% dextrose solution and stored at -80 °C until analysis.  The pDNA concentration was 
measured at 260 nm absorbance and adjusted to 1 mg/mL. 
For the preparation of ternary complexes, pDNA solution and PEI solution (pH 7.4) 
were mixed by pipetting thoroughly and left for 15 min at room temperature, and then 
each polynucleotide was mixed with pDNA/PEI complex by pipetting and left for 
another 15 min at room temperature.  In this study, we constructed those complexes at 
a theoretical charge ratio: phosphate of pDNA: nitrogen of PEI: phosphate of 
polynucleotide = 1:8:0 (pDNA/PEI complex), 1:8:2 (pDNA/PEI/polyA2, 
pDNA/PEI/polyU2, pDNA/PEI/polyC2, or pDNA/PEI/polyG2 complexes), 1:8:4 
(pDNA/PEI/polyA4, pDNA/PEI/polyU4, pDNA/PEI/polyC4, or pDNA/PEI/polyG4 
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complexes), 1:8:6 (pDNA/PEI/polyA6, pDNA/PEI/polyU6, pDNA/PEI/polyC6, or 
pDNA/PEI/polyG6 complexes), 1:8:8 (pDNA/PEI/polyA8, pDNA/PEI/polyU8, 
pDNA/PEI/polyC8, or pDNA/PEI/polyG8 complexes), and 1:8:10 (pDNA/PEI/polyA10, 
pDNA/PEI/polyU10, pDNA/PEI/polyC10, or pDNA/PEI/polyG10 complexes). 
 
2.3.  Physicochemical property of ternary complexes 
The particle sizes and ζ-potentials of complexes were measured using a Zetasizer 
Nano ZS (Malvern Instruments, Ltd., Malvern, United Kingdom).  The 
number-fractioned mean diameter is shown. 
To determine complex formations, 10 µL aliquots of complex solutions containing 1 
µg pDNA were mixed with 2 µL loading buffer (30% glycerol and 0.2% bromophenol 
blue) and loaded onto a 0.8% agarose gel. Electrophoresis (i-Mupid J; Cosmo Bio, 
Tokyo, Japan) was carried out at 50 V in running buffer solution (40 mM Tris/HCl, 40 
mM acetic acid, and 1 mM ethylenediaminetetraacetic acid (EDTA)) for 60 min.  The 
retardation of pDNA was visualized with ethidium bromide staining. 
 
2.4.  Transfection experiments 
The mouse melanoma cell line, B16-F10 cells, was obtained from the Cell Resource 
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Center for Biomedical Research (Tohoku University, Japan).  B16-F10 cells were 
maintained in RPMI 1640 supplemented with 10% FBS and antibiotics (culture 
medium) under a humidified atmosphere of 5% CO2 in air at 37 °C.  B16-F10 cells 
were plated on 24-well plates (Becton-Dickinson, Franklin Lakes, NJ, USA) at a density 
of 1.0 × 104 cells/well and cultivated in 0.5 mL culture medium.  In the transfection 
experiment, after 24 h pre-incubation, the medium was replaced with 0.5 mL 
Opti-MEM I medium (FBS (-)) or culture medium (FBS (+)) and each complex 
containing 1 µg pCMV-Luc was added to the cells and incubated for 2 h.  After 
transfection, the medium was replaced with culture medium and cells were cultured for 
a further 22 h at 37 °C.  After 22 h incubation, the cells were washed with PBS and 
then lysed in 100 µL lysis buffer (pH 7.8 and 0.1 M Tris/HCl buffer containing 0.05% 
Triton X-100 and 2 mM EDTA).  Ten microliters of lysate samples were mixed with 
50 µL luciferase assay buffer (PicaGene; Toyo Ink, Tokyo, Japan) and the light 
produced was immediately measured using a luminometer (Lumat LB 9507; EG & G 
Berthold, Bad Wildbad, German).  The protein content of the lysate was determined by 
a Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using BSA as a 
standard.  Absorbance was measured using a microplate reader (Sunrise RC-R; Tecan 
Japan Co., Ltd., Kanagawa, Japan) at 595 nm.  Luciferase activity was indicated as 
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relative light units (RLU) per mg protein. 
 
2.5.  WST-1 assay 
  Cytotoxicity tests of various complexes on B16-F10 cells were carried out using a 
WST-1 commercially available cell proliferation reagent.  WST-1 reagent was 
prepared (5 mM WST-1 and 0.2 mM 1-methoxy PMS in PBS) and filtered through a 
0.22 µm filter (Millex-GP; Millipore Co, Bedford, MA, USA) just before the 
experiments.  B16-F10 cells were plated on 96-well plates (Becton-Dickinson, 
Franklin Lakes, NJ, USA) at a density of 3.0 × 103 cells/well in the culture medium.  
The complexes containing 1 µg pDNA in 100 µL Opti-MEM I medium were added to 
each well and incubated for 2 h.  After incubation, the medium was replaced with 100 
µL culture medium and incubated for another 22 h.  Medium was replaced with 100 
µL culture medium and 10 µL of the WST-1 reagent was added to each well.  The cells 
were incubated for an additional 2 h at 37 °C, and absorbance was measured at a 
wavelength of 450 nm with a reference wavelength of 630 nm using a microplate reader.  
The results are shown as a percentage of untreated cells. 
 
2.6.  Fluorescent microscopy 
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To visualize the uptake of the complexes and gene expressions, B16-F10 cells were 
transfected by various complexes constructed with pEGFP-C1, Rh-PEI, and 
polynucleotide.  After 22 h incubation, the relative levels of Rh-PEI and GFP 
expression were characterized using fluorescent microscopy (200 × magnification; 
BZ-9000; KEYENCE, Osaka, Japan). 
 
2.7.  Inhibition study 
  For determination of the endocytotic pathway, after 23 h pre-incubation, the cells 
were treated with 0.014 mM chlorpromazine (CPZ) as an inhibitor of clathrin-mediated 
endocytosis, 0.2 mM genistein as an inhibitor of caveolae-mediated endocytosis, or 1 
mM amiloride as an inhibitor of macropinocytosis for 1 h.  After treatment, the 
pDNA/PEI/polyC6 complexes and pDNA/PEI complexes were added to the medium 
containing each inhibitor and incubated for 2 h.  After 2 h transfection, the medium 
was replaced with culture medium, cells were cultured for a further 22 h at 37 °C, and 
then the luciferase activities were determined. 
  For the inhibition study, the cells were transfected as described above with 
pDNA/PEI/polyC6 complexes in transfection medium containing various 
concentrations of polyC.  After transfection, the medium was replaced with culture 
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medium, cells were cultured for a further 22 h at 37 °C, and then luciferase activities 
were determined. 
 
2.8.  Morphology of pDNA/PEI/polyC 
  Transmission electron microscopy (JEM-1230; JEOL, Tokyo, Japan) was used to 
observe the configuration of pDNA/PEI/polyC6. 
 
2.9.  Animals 
  Animal care and experimental procedures were performed in accordance with the 
Guidelines for Animal Experimentation of Nagasaki University with approval from the 
Institutional Animal Care and Use Committee.  Male ddY mice (5-6 weeks old) were 
purchased from Japan SLC (Shizuoka, Japan).  After shipping, mice were acclimatized 
to the environment for at least one day before experiments. 
 
2.10.  Agglutination study 
Erythrocytes from mice were washed three times at 4 °C by centrifugation at 5000 
rpm (Kubota 3500; Kubota, Tokyo, Japan) for 5 min and resuspended in PBS.  A 2% 
(v/v) stock suspension was prepared.  Various complexes were added to the 
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erythrocytes (complexes: stock suspension = 1:1).  The suspensions were incubated for 
15 min at room temperature.  The 10 µL suspensions were placed on a glass plate and 
agglutination was observed by microscopy (200 × magnification). 
 
2.11.  In vivo study 
  Each complex containing 40 µg pCMV-Luc at a volume of 300 µL per mouse was 
injected intravenously into mice to examine the transgene efficacy of pDNA/PEI and 
pDNA/PEI/polyC6 complexes.  At 6 h following injection, the mice were sacrificed, 
and the liver, kidney, spleen, heart, and lung were dissected.  The tissues were washed 
twice with cold saline and homogenized with lysis buffer.  The homogenates were 
centrifuged at 15,000 rpm (Kubota 3500; Kubota) for 5 min and the supernatants were 
used for luciferase assays.  Luciferase activity was indicated as RLU per gram of 
tissue. 
  To evaluate the acute toxicity of pDNA/PEI and pDNA/PEI/polyC6 complexes, each 
complex containing 200 µg pCMV-Luc at a volume of 1.5 mL per mouse was injected 





2.12.  Statistical analysis 
Statistical significance between two groups was identified by Student’s t test. 
Multiple comparisons among groups were made by Dunnett’s pairwise multiple 
comparison t test.  
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3.  Results 
3.1.  Physicochemical characteristics and gel retardation assay 
  The particle size and ζ-potential of various complexes are shown in Table 1.  The 
pDNA/PEI complexes had 46.6 ± 5.5 nm particle size and 47.0 ± 0.5 mV ζ-potential.  
The pDNA/PEI/polyA, pDNA/PEI/polyU, and pDNA/PEI/polyC complexes with a 
charge ratio of polynucleotide to pDNA greater than 4 were less than 100 nm particle 
size, although pDNA/PEI/polyG complexes showed aggregation and particle size was 
not detected.  Addition of polynucleotides decreased the ζ-potential of pDNA/PEI 
complexes concentration-dependently.  The pDNA/PEI/polyA, pDNA/PEI/polyU, and 
pDNA/PEI/polyC complexes with a charge ratio greater than 4 showed an anionic 
surface charge. 
  Complex formations were examined by a gel retardation assay (Fig. 1).  Naked 
pDNA was detected as a band on agarose gel.  The complexes showed no band of 
pDNA, which was released. 
  On the basis of the results of physicochemical properties, we performed further 





3.2.  In vitro transfection efficiency 
  The complexes were incubated with B16-F10 cells and luciferase activity in the cells 
was determined.  The in vitro transgene efficiencies of the complexes at various charge 
ratios are shown in Fig. 2.  The pDNA/PEI complexes exceeded 1010 RLU/mg protein 
in transgene efficiency.  Addition of polynucleotides to pDNA/PEI complexes 
decreased luciferase activities with an increase of the amount.  The pDNA/PEI/polyC 
complexes retained high gene expression over 109 RLU/mg protein, although 
pDNA/PEI/polyA complexes and pDNA/PEI/polyU complexes showed low gene 
expression of less than 109 RLU/mg protein. 
 
3.3.  Cellular toxicity 
  Each complex was added to B16-F10 cells and cell viability was evaluated by WST-1 
assay (Fig. 3).  The pDNA/PEI complexes showed significantly higher cellular toxicity 
than the control (P < 0.01).  On the other hand, no cellular toxicity was observed in the 
pDNA/PEI/polyA complexes.  The pDNA/PEI/polyU complexes showed moderate 
cytotoxicity concentration-dependently.  The addition of polyC decreased the 
cytotoxicity of pDNA/PEI complexes, and the pDNA/PEI/polyC complexes with a 




3.4.  Fluorescent microscopy 
  The cellular uptake and gene expression were visualized in the pDNA/PEI/polyA6, 
pDNA/PEI/polyU6, and pDNA/PEI/polyC6 complexes. B16-F10 cells were transfected 
with the complexes containing Rh-PEI and pEGFP-C1 (Fig. 4). 
  The pDNA/PEI complexes and pDNA/PEI/polyC6 complexes showed red dots of 
Rh-PEI in the cells.  The bright green fluorescence of GFP was observed in the cells 
transfected with pDNA/PEI complexes and pDNA/PEI/polyC6 complexes, although no 
fluorescence was observed in pDNA/PEI/polyA6 complexes and pDNA/PEI/polyU6 
complexes. 
 
3.5.  Inhibition study 
  The gene expression of pDNA/PEI/polyC6 complexes in medium containing various 
concentrations of polyC is shown in Fig. 5A.  PolyC significantly inhibited the 
transgene efficiency of pDNA/PEI/polyC6 complexes concentration-dependently.  Fig. 
5B shows the influence of endocytotic inhibitors on the transgene efficiency of 
pDNA/PEI/polyC6 complexes and pDNA/PEI complexes.  All endocytotic inhibitors 
decreased the transgene efficiency of pDNA/PEI/polyC6 complexes.  Especially, the 
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inhibition of caveolae-mediated endocytosis with genistein significantly decreased the 
transgene efficiency of the pDNA/PEI/polyC6 complexes (P < 0.01), which was lower 
than 20%.  On the other hand, the transgene efficacy of pDNA/PEI complexes was 
only suppressed by the addition of genistein.  Chlorpromazine and amiloride had little 
effect on the transgene efficiency of the pDNA /PEI complexes. 
 
3.6.  The effect of serum on the transgene efficiency 
  The effect of serum on transgene efficiencies of the complexes was examined.  
pDNA/PEI/polyC complexes were unaffected by serum.  On the other hand, the 
transfection effect of pDNA/PEI complexes was decreased by serum (Fig. 6). 
 
3.7.  Morphology of pDNA/PEI/polyC 
  pDNA/PEI/polyC6 complexes was observed as clumped nano-particles in the TEM 
(Fig. 7). 
 
3.8.  In vivo study 
  In vivo transgene efficiency of pDNA/PEI complexes and pDNA/PEI/polyC6 
complexes, which showed high transgene efficiency in an in vitro experiment, was 
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examined in ddY male mice and is shown in Fig. 8.  Luciferase activities in several 
tissues were determined 6 h after intravenous administration of the complexes.  The 
pDNA/PEI complexes showed high gene expression in all tissues.  On the other hand, 
pDNA/PEI/polyC6 complexes showed high gene expression selectively in the spleen. 
 
3.9.  In vivo acute toxicity and agglutination study 
  In vivo acute toxicity of pDNA/PEI and pDNA/PEI/polyC6 complexes was evaluated 
by the survival rate 24 h after intravenous infection of the complexes to ddY male mice.  
All mice survived the injection of pDNA/PEI/polyC6 complexes, although 4 of 9 mice 
died after injection of pDNA/PEI complexes (Fig. 9A).   
Agglutination activities of pDNA/PEI/polyC6 complexes were compared to 
pDNA/PEI complexes in erythrocytes (Fig. 9B).  The pDNA/PEI/polyC6 complexes 





4.  Discussion 
  Advances in the field of non-viral gene therapy have been the subject of intensive 
research because of the inherent safety issues associated with most viral vectors. 
Numerous non-viral vectors for increasing transfection efficiencies and decreasing 
toxicities have been developed.  Among the non-viral vectors, cationic lipids and 
cationic polymers are the most probable alternatives to viral vectors and are increasingly 
being used in vitro and in vivo (Gao et al., 2007).  A cationic polymer (at physiological 
pH) can be combined with DNA to form a particulate complex, polyplex, capable of 
gene transfer to the targeted cells (Pezzoli et al., 2012).  The most obvious difference 
of cationic polymers from cationic lipids is that they do not contain a hydrophobic 
moiety and are completely soluble in water.  Compared with cationic lipids, cationic 
polymers have the obvious advantage of compressing DNA molecules to a relatively 
small size.  PEI is one of the most studied and employed non-viral gene carriers.  
Many factors affect the efficiency/cytotoxicity profile of PEI polyplexes, such as 
molecular weight, degree of branching, zeta potential and particle size (Kunath et al., 
2003; Kircheis et al., 1999).  PEI is known to cause severe adverse effects such as 
cytotoxicity and agglutination.  The toxic effect is mainly determined by the cationic 
nature of PEI (Lv et al., 2006; Pack et al., 2005; Lugwitz et al., 2005). 
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Here, we hypothesized that anionic polymer-coating of complexes of pDNA and PEI 
could improve toxicity of PEI.  Among anionic polymers, polynucleotides were 
expected to transfer the complexes into the targeted cells through a specific uptake 
mechanism.  PolyA, polyU, polyC, and polyG were used as a coating material with 
large molecular weight and relatively stable properties. 
We checked the physicochemical properties of the ternary complexes.  Table 1 
shows the particle size and ζ-potential of the complexes.  The pDNA/PEI/polyA, 
pDNA/PEI/polyU, and pDNA/PEI/polyC complexes with a charge ratio greater than 4 
showed less than 100 nm particle size and a negative surface charge; indicating the 
particle sizes of the ternary complexes were suitable for in vivo gene delivery.  The 
negative surface charge of the ternary complexes suggested that polynucleotides 
effectively coated the particles.  Furthermore, the size and ζ-potential of pDNA/PEI/ 
polyA, pDNA/PEI/polyU, and pDNA/PEI/polyC complexes were not changed in serum 
(data not shown); thus, stability of the ternary complexes was expected to be good 
enough for in vivo applications.  Some polyanions such as heparin are known to 
release pDNA from pDNA/PEI complexes (Moret et al., 2001).  However, we found 
that the addition of polynucleotides did not push pDNA out of particles (Fig. 1).  
Furthermore, the presence of serum did not promote pDNA release from the ternary 
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complexes (data not shown).  These results support that pDNA/PEI/ polyA, 
pDNA/PEI/polyU, and pDNA/PEI/polyC complexes are stable as self-assembled 
nano-particles without de-complexation, even in blood. 
  The in vitro transgene efficiency was evaluated with B16-F10 cells by luciferase 
activity (Fig. 2).  The pDNA/PEI complexes exceeded 1010 RLU/mg protein in 
transgene efficiency.  Addition of polynucleotides to pDNA/PEI complexes decreased 
luciferase activities concentration-dependently.  These results reflect the low 
interaction of the negative surface charge of complexes with the cellular surface (Chen 
et al., 2011; Fröhlich, 2012).  In particular, the pDNA/PEI/polyA complexes and 
pDNA/PEI/polyU complexes showed low gene expression after the addition of 
polynucleotides.  In fact, cellular uptake of Rh-PEI was not observed in the 
pDNA/PEI/polyA complexes and pDNA/PEI/polyU complexes at a charge ratio of 6 
(Fig. 4).  On the other hand, the pDNA/PEI/polyC complexes retained high gene 
expression over 109 RLU/mg protein and showed cellular uptake of Rh-PEI and gene 
expression of GFP.  These results suggest that the uptake mechanism of 
pDNA/PEI/polynucleotide complexes differs with the type of polynucleotide and that 
there is a specific uptake mechanism of pDNA/PEI/polyC complexes.  
pDNA/PEI/polyC complexes must release DNA so that it can be transported into the 
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nucleus, although the detailed mechanism is unclear. 
  We therefore performed an inhibition study with polyC and various endocytotic 
inhibitors.  The gene transfection of pDNA/PEI/polyC6 complexes was inhibited by 
polyC concentration-dependently.  These results strongly indicate the specific uptake 
mechanism of pDNA/PEI/polyC complexes.  CPZ, genistein, and amiloride all 
suppressed the transgene expression efficiency of the pDNA/PEI/polyC6 complexes, 
suggesting that it was taken up by the cells via several mechanisms.  Among inhibitors, 
genistein especially suppressed the gene expression of pDNA/PEI/polyC6 complexes.  
These results showed that the pDNA/PEI/polyC6 complexes were mainly taken up by 
caveolae-mediated endocytosis.  It is generally believed that caveolar uptake does not 
lead to lysosomal degradation (Harris et al. 2002; Ferrari et al., 2003).  Therefore, 
pDNA/PEI/polyC6 complexes seem to be advantageous in terms of DNA delivery.  On 
the other hand, the transgene expression efficiency of the pDNA/PEI complexes was 
only suppressed by genistein.  These results suggested that the uptake mechanism of 
pDNA/PEI/polyC complexes differed from that of pDNA/PEI complexes. 
  We confirmed that the particle size of pDNA/PEI/polyC6 complexes was suitable for 
in vivo gene delivery using TEM (Fig. 7).  Then, in vivo transgene efficiency of 
pDNA/PEI/polyC6 complexes, which showed high transgene efficiency and low 
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cytotoxicity in vitro (Figs. 2 and 3), was examined in ddY male mice (Fig. 8).  Naked 
pDNA did not show gene expression in any tissues (data not shown).  The 
pDNA/PEI/polyC6 complexes showed high gene expression selectively in the spleen, 
although pDNA/PEI complexes showed gene expression non-selectively in all tissues.  
The positive charges of polyplexes are known to strongly interact with the negative 
surface of the cellular membrane and be taken up by endothelial cells through 
endocytosis.  The strong positive charge of pDNA/PEI complexes may contribute to 
the high gene expression in all tissues.  On the other hand, the high gene expression in 
the spleen of pDNA/PEI/polyC complexes may result in the low serum effect (Fig. 6).  
The spleen plays important roles in regard to erythrocytes and the immune system 
(Cesta, 2006; Zandvoort et al., 2002), acting primarily as a blood filter and having many 
macrophages and dendritic cells, which express many types of receptors that mediate 
the endocytosis of a broad range of polyanionic molecules.  A specific uptake 
mechanism of pDNA/PEI/polyC complexes was strongly suggested in the present 
study; therefore, pDNA/PEI/polyC complexes may show specifically high transgene 
efficiency in the spleen.  A splenic gene delivery system must be a promising approach 
for DNA vaccination.  We have already demonstrated that a splenic gene delivery 
system markedly inhibited malaria infection in mice (Cherif et al., 2011).  
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  There were mainly two types of cytotoxicity in the process of PEI-mediated cell 
transfection; immediate toxicity associated with free PEI and delayed toxicity associated 
with cellular processing of pDNA/PEI complexes (Godbey et al., 2001).  The 
pDNA/PEI complexes showed significant cellular toxicity (Fig. 3).  On the other hand, 
the ternary complexes reduced cytotoxicity.  The negative surface charge of the 
polynucleotide-coating complexes may result in their safety because of low interaction 
with the cellular membrane.  When administered into the circulatory system, the free 
PEIs interacted with negatively charged serum proteins and red blood cells, precipitated 
in huge clusters and adhered to the cellular surface (Lv et al. 2006).  This effect could 
destabilize the plasma membrane and induce immediate toxicity.  In fact, the 
pDNA/PEI complexes showed severe agglutination with erythrocytes.  Four of 9 mice 
had died 24 h after injection of pDNA/PEI complexes at a 5-fold dose; however, 
pDNA/PEI/polyC6 complexes showed no agglutination with erythrocytes and acute 
toxicity (Fig. 9).  These results indicate the high safety of pDNA/PEI/polyC complexes 





5.  Conclusion 
  In this study, we developed polynucleotide-coating complexes as a novel vector for 
clinical gene therapy.  This vector consisted of stable particles with apparently 
negative ζ-potential.  In particular, the pDNA/PEI/polyC6 complexes showed high in 
vitro gene expression without cytotoxicity.  The inhibition study suggested the specific 
uptake mechanism of pDNA/PEI/polyC6 complexes.  The pDNA/PEI/polyC6 
complexes showed selective in vivo gene expression in the spleen, showing neither 
agglutination with erythrocytes nor acute toxicity.  The pDNA/PEI/polyC6 complexes 
are a useful candidate for a gene delivery system.  Further studies are necessary to 
reveal the detail uptake pathway of polyC. 
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Fig. 1.  Gel retardation assay of each polynucleotide coating complex.  Each complex 
was loaded onto agarose gel, and electrophoresis was carried out.  Retardation of 
pDNA was visualized using ethidium bromide.  (A): pDNA/PEI/polyA complexes; 
(B): pDNA/PEI/polyU complexes; (C): pDNA/PEI/polyC complexes; (D): 
pDNA/PEI/polyG complexes. 
 
Fig. 2.  In vitro transgene efficiency in B16-F10 cells of pDNA/PEI/polyA complexes 
(A), pDNA/PEI/polyU complexes (B), and pDNA/PEI/polyC complexes (C).  
B16-F10 cells were transfected with each complex containing pCMV-Luc in Opti-MEM.   
Twenty-two hours after transfection, luciferase activity was evaluated.  Each bar 
represents the mean ± S.E. of three experiments. 
 
Fig. 3.  Cytotoxicity of various complexes on B16-F10 cells.  Viability of cells treated 
with pDNA/PEI/polyA complexes (A), pDNA/PEI/polyU complexes (B), and 
pDNA/PEI/polyC complexes was measured by WST-1 assay.  Cells were incubated 
with each complex for 2 h and cell viability was measured 22 h after treatment.  Data 
are the percentage to untreated cells.  Each bar represents the mean ± S.E. of eight 
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experiments.  *: P < 0.05, **: P < 0.01 vs control. 
 
Fig. 4.  Fluorescent microscopy images of B16-F10 cells transfected with each 
complex.  Cells were transfected with each complex containing pEGFP-C1 and 
Rh-PEI.  Twenty-four hours after transfection, the uptake of Rh-PEI (A) and the 
expression of GFP (B) were monitored (200 × magnification).  (a): pDNA/PEI; (b): 
pDNA/PEI/polyA; (c): pDNA/PEI/polyU; (d): pDNA/PEI/polyC. 
 
Fig. 5.  Influence of polyC (A) and endocytotic inhibitors (B) on transgene efficiency. 
(A) pDNA/PEI/polyC6 complexes were transfected in medium containing various 
concentrations of polyC.  (B) pDNA/PEI/polyC6 complexes and pDNA/PEI 
complexes were transfected in medium with various endocytotic inhibitors.  After 22 h 
transfection, luciferase activities were evaluated. pDNA/PEI/polyC6 complex (  ), 
pDNA/PEI complex (  ).  Each bar represents the mean ± S. E. of three experiments.  
*: P < 0.05, **: P < 0.01 vs control. 
 
Fig. 6.  Influence of serum on transgene efficiency of the complexes.  B16-F10 cells 
were transfected with each complex containing pCMV-Luc in culture medium.   
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Twenty-two hours after transfection, luciferase activity was evaluated.  Each bar 
represents the mean ± S.E. of three experiments. 
 
Fig. 7.  Transmission Electron Microscopy (TEM) Image of pDNA/PEI/polyC6 
complexes. 
 
Fig. 8.  In vivo transgene efficiencies of the pDNA/PEI (A) and pDNA/PEI/polyC6 (B) 
complexes in mice.  The complexes were injected intravenously into mice (40 µg DNA 
per mouse).  At 6 h after injection, mice were sacrificed and each organ was dissected 
to quantify luciferase activity.  Each bar represents the mean ± S.E. (n = 3-6). 
 
Fig. 9.  Acute toxicity (A) and agglutination with erythrocytes (B) of the complexes.  
(A) Surviving mice were counted 24 h after injection of each complex.  (B) Each 
complex was added to erythrocytes, and agglutination was observed by microscopy 
(200 × magnification). 
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